{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:21Z","timestamp":1707524901973},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,9]]},"DOI":"10.7759\/cureus.33538","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T14:56:47Z","timestamp":1673276207000},"source":"Crossref","is-referenced-by-count":0,"title":["Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Farhan","family":"Azad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive J","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0012","article-title":"Clonal expansion and interrelatedness of distinct B-lineage compartments in multiple myeloma bone marrow","volume":"5","author":"Hansmann L","year":"2017","unstructured":"Hansmann L, Han A, Penter L, Liedtke M, Davis MM. Clonal expansion and interrelatedness of distinct B-lineage compartments in multiple myeloma bone marrow. Cancer Immunol Res. 2017, 5:744-54. 10.1158\/2326-6066.CIR-17-0012","journal-title":"Cancer Immunol Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.130091","article-title":"Tumor lysis syndrome in multiple myeloma treated with bortezomib","volume":"5","author":"Dhanraj KM","year":"2014","unstructured":"Dhanraj KM, Biswajit D. Tumor lysis syndrome in multiple myeloma treated with bortezomib. J Pharmacol Pharmacother. 2014, 5:161-2. 10.4103\/0976-500X.130091","journal-title":"J Pharmacol Pharmacother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1397","article-title":"Carfilzomib-associated tumor lysis syndrome","volume":"34","author":"Shely RN","year":"2014","unstructured":"Shely RN, Ratliff PD. Carfilzomib-associated tumor lysis syndrome. Pharmacotherapy. 2014, 34:e34-7. 10.1002\/phar.1397","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217729564","article-title":"Cardiotoxicity with carfilzomib at doses greater than 27\u2009mg\/m(2): a case series","volume":"25","author":"Kim GY","year":"2019","unstructured":"Kim GY, Ahuja T, Papadopoulos J, Cirrone F. Cardiotoxicity with carfilzomib at doses greater than 27\u2009mg\/m(2): a case series. J Oncol Pharm Pract. 2019, 25:229-33. 10.1177\/1078155217729564","journal-title":"J Oncol Pharm Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070209-175325","article-title":"Multiple myeloma","volume":"62","author":"Laubach J","year":"2011","unstructured":"Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011, 62:249-64. 10.1146\/annurev-med-070209-175325","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau P","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012, 120:947-59. 10.1182\/blood-2012-04-403733","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse A","year":"2019","unstructured":"Besse A, Besse L, Kraus M, et al.. Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors. Cell Chem Biol. 2019, 26:340-51.e3. 10.1016\/j.chembiol.2018.11.007","journal-title":"Cell Chem Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12327","article-title":"Tumor lysis syndrome: current perspective","volume":"93","author":"Hochberg J","year":"2008","unstructured":"Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica. 2008, 93:9-13. 10.3324\/haematol.12327","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-016-0731-6","article-title":"Tumor lysis syndrome in multiple myeloma: an increasingly recognized risk-a report of seven cases","volume":"33","author":"Singh A","year":"2017","unstructured":"Singh A, Gupta S, Yim B, Thekkekara R.  Tumor lysis syndrome in multiple myeloma: an increasingly recognized risk-a report of seven cases. Indian J Hematol Blood Transfus. 2017, 33:41-4. 10.1007\/s12288-016-0731-6","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S62512","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey RD","year":"2014","unstructured":"Harvey RD. Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol. 2014, 6:87-96. 10.2147\/CPAA.S62512","journal-title":"Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11274","article-title":"High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib","volume":"36","author":"Oiwa K","year":"2016","unstructured":"Oiwa K, Morita M, Kishi S, et al.. High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib. Anticancer Res. 2016, 36:6655-62. 10.21873\/anticanres.11274","journal-title":"Anticancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler KD","year":"2017","unstructured":"Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A. Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study. Clin Lymphoma Myeloma Leuk. 2017, 17:89-96.e3. 10.1016\/j.clml.2016.11.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress","volume":"17","author":"Imam F","year":"2017","unstructured":"Imam F, Al-Harbi NO, Al-Harbia MM, et al.. Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress. Cardiovasc Toxicol. 2017, 17:58-66. 10.1007\/s12012-015-9356-5","journal-title":"Cardiovasc Toxicol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff BB","year":"2017","unstructured":"Hasinoff BB, Patel D, Wu X. Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovasc Toxicol. 2017, 17:237-50. 10.1007\/s12012-016-9378-7","journal-title":"Cardiovasc Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli C","year":"2017","unstructured":"Chen-Scarabelli C, Corsetti G, Pasini E, et al.. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine. 2017, 21:206-12. 10.1016\/j.ebiom.2017.05.024","journal-title":"EBioMedicine"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell RF","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, et al.. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019, 37:1946-55. 10.1200\/JCO.19.00231","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari A","year":"2018","unstructured":"Chari A, Stewart AK, Russell SD, et al.. Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials. Blood Adv. 2018, 2:1633-44. 10.1182\/bloodadvances.2017015545","journal-title":"Blood Adv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2535","article-title":"Carfilzomib-associated cardiovascular adverse events in a non-Caucasian cohort of patients with multiple myeloma: a real-world experience","volume":"36","author":"Mangla A","year":"2018","unstructured":"Mangla A, Paydary K, Liu J, Mbachi C, Yim B, Lad TE. Carfilzomib-associated cardiovascular adverse events in a non-Caucasian cohort of patients with multiple myeloma: a real-world experience. Hematol Oncol. 2018, 36:715-7. 10.1002\/hon.2535","journal-title":"Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon TM","year":"2013","unstructured":"Herndon TM, Deisseroth A, Kaminskas E, et al.. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013, 19:4559-63. 10.1158\/1078-0432.CCR-13-0755","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S39085","article-title":"Targeted treatments for multiple myeloma: specific role of carfilzomib","volume":"8","author":"Sugumar D","year":"2015","unstructured":"Sugumar D, Keller J, Vij R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med. 2015, 8:23-33. 10.2147\/PGPM.S39085","journal-title":"Pharmgenomics Pers Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131913-carfilzomib-induced-tumor-lysis-syndrome-and-biventricular-heart-failure-in-a-patient-with-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:45Z","timestamp":1707508425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131913-carfilzomib-induced-tumor-lysis-syndrome-and-biventricular-heart-failure-in-a-patient-with-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.33538","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}